Inflammatory rheumatic diseases affect 1% of the population. Treatment of such diseases should be based on disease activity, safety issues and other patient characteristics such as comorbidities (EULAR, 2022), leading to a higher risk of cardiovascular diseases. To this end, the general treat-to-target approach, as recommended in the EULAR guidance, may require several successive treatment lines based on updates to the patients' profile and close monitoring as the keystone of its implementation.
Regular feedback from patients could be used to fuel such strategies. This feedback can be collected using an ePRO (electronic Patient Reported Outcome). The purpose of this study is therefore to assess patient management using the information provided by patients through e-PROs, which will transfer the data provided by the patient to the physician and will notify the investigators via email when a patient has completed a form (no data interpretation or alerts).
The hypothesis is that the more physicians are provided with insights into their patients' health, the more they will function in a treat-to-target approach and the more often they will tend to adjust their patients' treatments.
Men or women of at least 18 years of age
Rheumatoid arthritis (RA) according to the 2010 EULAR/ACR classification criteria,
Gout according to the 2015 EULAR/ACR classification criteria,
Systemic lupus erythematosus according to the 2019 EULAR/ACR classification criteria
Any neurodegenerative disease that alters cognitive faculties
Refractory cancer
Patients who do not have access to the Internet and/or do not master its use in the context of this protocol
Unwillingness or inability to adhere to study protocol (language barriers, cognitive disorders…) Subject who is compulsorily detained for psychiatric treatment
Patient with Gout, Rheumatoid arthritis, Sjogren's syndrome or Systemic lupus erythematosus
Cohort
Prospective
Therapeutic management following access by the physician to his patient's ePROs
BehavioralTherapeutic management following access by the physician to his patient's ePROs
Frequency of therapeutic adjustments
To assess the relationship between the frequency of therapeutic adjustments over a 12-month period made by rheumatologists who were provided regular patient reported outcomes (PROs) and their use of an electronic platform providing them with these data.
Frequency of therapeutic adjustments
To assess the relationship between the frequency of therapeutic adjustments over a 6-month period made by rheumatologists who were provided regular patient reported outcomes (PROs) and their use of an electronic platform providing them with these data.
Frequency of therapeutic adjustments
To assess the relationship between the frequency of therapeutic adjustments over a 24-month period made by rheumatologists who were provided regular patient reported outcomes (PROs) and their use of an electronic platform providing them with these data.
Frequency of flares and exacerbation
To assess the fluctuation of disease activity and flares - as perceived by the patient
Frequency of flares and exacerbation
To assess the fluctuation of disease activity and flares - as perceived by the patient
Click on the lead sponsor to view all of their trials.
